Difference between revisions of "MCARH-109"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-gprc5d-car-4-1bb-expressing-t-cells-mcarh109 NCI Drug Dictio...") |
Warner-admin (talk | contribs) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Multiple myeloma]]=== | ===[[Multiple myeloma]]=== | ||
| − | #'''MSKCC 18-367:''' Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivière I, Brentjens RJ, Smith EL. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022 Sep 29;387(13):1196-1206. [https://doi.org/10.1056/nejmoa2209900 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36170501/ PubMed] NCT04555551 | + | #'''MSKCC 18-367:''' Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivière I, Brentjens RJ, Smith EL. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022 Sep 29;387(13):1196-1206. [https://doi.org/10.1056/nejmoa2209900 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36170501/ PubMed] [https://clinicaltrials.gov/study/NCT04555551 NCT04555551] |
| − | [[Category: | + | [[Category:Anti-GPRC5D CAR T-cells]] |
[[Category:Anti-CD137 cellular therapy]] | [[Category:Anti-CD137 cellular therapy]] | ||
[[Category:Anti-GPRC5D cellular therapy]] | [[Category:Anti-GPRC5D cellular therapy]] | ||
Latest revision as of 12:24, 27 July 2023
Mechanism of action
From the NCI Drug Dictionary: A preparation of autologous T lymphocytes that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D) and the co-stimulatory domain 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-GPRC5D-CAR-4-1BB-expressing T cells MCARH109 specifically recognize and induce selective toxicity in GPRC5D-expressing tumor cells.
Preliminary data
Multiple myeloma
- MSKCC 18-367: Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivière I, Brentjens RJ, Smith EL. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022 Sep 29;387(13):1196-1206. link to original article PubMed NCT04555551